MRSA drug dosage calculations found to be inaccurate for children over 10

The emergence of MRSA (Staphylococcus aureus), dubbed a 'superbug' due to its resistance to many antibiotic drugs, has resulted in the glycopeptide antibiotic Vancomycin being commonly prescribed for patients in hospital.

However, MRSA's resistance to drugs has led to concerns of a 'creeping minimum' in the concentration of the dosage required to treat infection. In , nomograms are used to calculate the correct dosage of Vancomycin based on a patient's weight and creatinine levels.

While these adult nomograms are widely thought to be suitable for teenagers, pharmacological differences between teens and young adults remain poorly understood.

New research, published in the Journal of Clinical Pharmacology, explores the accuracy of adult nomograms in children over ten. The results of 120 patients from a children's' hospital in Vanderbilt, Nashville, revealed that Vancomycin nomograms from adults were not accurate in predicting appropriate dosing levels in .

"Based on the variability of pharmacokinetic parameters and drug clearance, the two Vancomycin nomograms developed to predict therapeutic Vancomycin concentrations in healthy adults did not accurately estimate dosage regimens in older children regardless of weight or age, and therefore should not be used to aid empiric dosing," said Dr. Jessica Gillon. "Further prospective studies are warranted for teens between 10 and 18 years of age to determine the most appropriate Vancomycin dosing to maximize drug efficacy and reduce the risk of Vancomycin induced renal toxicity."

More information: Jessica E. Gillon, James E. Cassat, M. Cecilia Di Pentima, 'Validation of two vancomycin nomograms in patients 10 years of age and older' The Journal of Clinical Pharmacology, Wiley, DOI: 10.1002/jcph.173

add to favorites email to friend print save as pdf

Related Stories

Less commonly prescribed antibiotic may be better

Aug 16, 2012

The antibiotic most commonly prescribed to treat bloodstream infections in dialysis patients may not always be the best choice, according to a study appearing in an upcoming issue of the Journal of the American Society of ...

Vibativ approved for certain bacterial pneumonia

Jun 24, 2013

(HealthDay)—The antibiotic Vibativ (telavancin) has been approved by the U.S. Food and Drug Administration to treat pneumonia caused by Staphylococcus aureus bacteria when other treatments aren't suitable.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments